INNA-051 Drug Asset Due Diligence Report 2026

This INNA-051 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether INNA-051 can convert its Small molecule drug profile and TLR2 x TLR6 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	INNA-051 (query alias: INNA-051)
Modality / target	Small molecule drug; TLR2 x TLR6; TLR2 agonists, TLR6 agonists, Immunostimulants
Highest global status	Phase 2
Originator	Ena Respiratory Pty Ltd.
Active developers	Ena Respiratory Pty Ltd.

The MCP disease footprint includes Viral respiratory infection, Influenza, Human. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ACTRN12626000037303	Phase 1	Not yet recruiting	20	Primary endpoint not disclosed in English source
NCT07222670	Phase 2	Recruiting	1100	Primary endpoint not disclosed in English source
ACTRN12624000635561	Phase 1	Completed	48	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

ENA Respiratory Announces Publication Supporting the Potential of its Novel Intranasal Therapy INNA-051 to Reduce the Impact of Viral Respiratory Infections in Older Adults

Phase 1; n=not disclosed; evaluation: Positive. Reported fields: Efficacy = Biomarker analysis showed that INNA-051 triggered host defence pathways within eight hours of each dose. ; Efficacy = Biomarker analysis showed that INNA-051 triggered host defence pathways within eight hours of each dose.

INNA-051 prophylaxis enhances innate immune responses confirming accelerated viral clearnace in a human influenza challenge model.

Phase 2; n=123; evaluation: Positive. Reported fields: Response = INNA-051 was found to increase host responses against influenza and interferon type I & III gene expression compared to placebo treatment, reflecting accelerated viral clearance observed in this study

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

INNA-051 addresses Viral respiratory infection, Influenza, Human. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2022-02-23	ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO